Inozyme Pharma Inc INZY:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
Last | 04/30/24 EDT
4.41quote price arrow down-0.01 (-0.23%)
Volume
626,846
52 week range
2.69 - 7.80
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.41
  • 52 Week High7.80
  • 52 Week High Date04/01/24
  • 52 Week Low2.69
  • 52 Week Low Date10/27/23

Key Stats

  • Market Cap272.414M
  • Shares Out61.77M
  • 10 Day Average Volume0.60M
  • Dividend-
  • Dividend Yield-
  • Beta1.50
  • YTD % Change3.52

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.41
  • 52 Week High7.80
  • 52 Week High Date04/01/24
  • 52 Week Low2.69
  • 52 Week Low Date10/27/23
  • Market Cap272.414M
  • Shares Out61.77M
  • 10 Day Average Volume0.60M
  • Dividend-
  • Dividend Yield-
  • Beta1.50
  • YTD % Change3.52

RATIOS/PROFITABILITY

  • EPS (TTM)-1.39
  • P/E (TTM)-3.18
  • Fwd P/E (NTM)-2.94
  • EBITDA (TTM)-74.812M
  • ROE (TTM)-54.98%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)31.87%

EVENTS

  • Earnings Date05/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Inozyme Pharma Inc

 

Profile

MORE
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate...
Douglas Treco Ph.D.
Chairman of the Board, Chief Executive Officer
Matthew Winton
Chief Operations Officer
Sanjay Subramanian
Chief Financial Officer
Address
321 SUMMER STREET, SUITE 400
Boston, MA
02210
United States

Top Peers

SYMBOLLASTCHG%CHG
VTYX
Ventyx Biosciences Inc
3.74-0.09-2.48%
GLUE
Monte Rosa Therapeutics Inc
5.32-0.29-5.17%
RAPT
RAPT Therapeutics Inc
7.70-0.18-2.28%
OPT
Opthea Ltd
3.34+0.07+2.14%
AVXL
Anavex Life Sciences Corp
3.65UNCHUNCH